أبوكيل أقراص وأقراص قابلة للمضغ
Apoquel (oclacitinib tablet and chewable tablet) is a targeted Janus kinase (JAK-1) inhibitor indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. Provides fast itch relief within 4 hours, comparable to steroids, without steroid-associated side effects.
الشكل الصيدلاني
Tablet
نوع المنتج
دواء
الشركة المصنعة
الحجم
Bottles of 20, 100, and 250 tablets or chewable tablets (3.6 mg, 5.4 mg, and 16 mg)
| النوع الحيواني | الجرعة | طريقة الإعطاء | المدة |
|---|---|---|---|
| Dog | 0.4 to 0.6 mg oclacitinib/kg body weight | Oral (PO) | Twice daily for up to 14 days, then once daily for maintenance |
لا توجد معلومات سحب متاحة.
Control of pruritus associated with allergic dermatitis in dogs at least 12 months of age.
Control of atopic dermatitis in dogs at least 12 months of age.
Do not use in dogs less than 12 months of age.
Do not use in dogs with serious infections.
Do not use in breeding dogs, pregnant, or lactating bitches.
Apoquel modulates the immune system and may increase susceptibility to infections, including demodicosis and neoplasia.
Monitor dogs receiving long-term treatment with complete blood counts and serum chemistry periodically.
Most common side effects include vomiting, diarrhea, anorexia, lethargy, and localized skin infections.
Apoquel Tablets & Chewables Prescribing Information
نشرةلا توجد أمراض مرتبطة.
لا توجد بيانات
لم تتم إضافة المعلومات بعد.
لا توجد بيانات
لم تتم إضافة المعلومات بعد.
شركة مصنعة
لا توجد بدائل متاحة.